Why hasn’t Cabozantinib entered China?

Cabozantinib (Cabozantinib) has not yet been launched in China. This means that at this point in time, cabozantinib has not yet been approved by the National Medical Products Administration (NMPA) in China and has not been sold and used in China.

The drug development, registration and marketing process may be complex and may involve clinical trials, approval processes and compliance with local drug regulatory regulations. It may take some time for some drugs to enter the Chinese market after being approved in other countries.

If you are interested in the latest situation of cabozantinib in China, it is recommended to consult the China National Medical Products Administration (NMPA) or relevant drug registration agencies to obtain the latest information and progress. At the same time, you can also pay attention to news released by the health department or pharmaceutical industry media to obtain relevant updates. Please note that the registration and marketing status of a drug may change over time.

Cabozantinib is not currently on the market in China and is therefore not included in medical insurance because it requires approval from the National Medical Products Administration. Therefore, patients cannot purchase it domestically and need to purchase it through overseas channels. There are original and generic cabozantinib drugs abroad. The original drugs are mainly Japanese original drugs, Turkish original drugs and European version original drugs. The price is relatively high, ranging from 35,000 to 46,000 yuan. Foreign generic drugs are mainly Lao generic drugs and Bangladeshi generic drugs, with prices ranging from 1,300 to 2,700 yuan. The price is much cheaper than original drugs and is more suitable for the needs of patients in ordinary families. The ingredients of original drugs and generic drugs are basically the same.